News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

rEVO Biologics Announces Enrollment Of First Patient In Phase 3 Trial Of Atryn® To Treat Early Onset Preeclampsia (PRESERVE-1)


7/24/2014 11:48:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics, Inc., a subsidiary of LFB Biotechnologies, today announced the enrollment of the first patient in its Phase 3 clinical trial of ATryn® [antithrombin (Recombinant)], for the treatment of preeclampsia during the 24th to 28th week of pregnancy, or early onset preeclampsia. The objective of the PRESERVE-1 trial is to assess whether ATryn prolongs pregnancy in mothers with early onset preeclampsia, consequently reducing the high rates of neonatal mortality and disability caused by this condition.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES